logo-loader
viewGenedrive PLC

Notice of Results

/**/ h2{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:10.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;line-height:15.0pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight:bold;}h4{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight:bold;}h5{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:8.0pt;font-family:"Arial","sans-serif";letter-spacing:-.2pt;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .da{size:595.3pt 841.9pt;margin:72.1pt 42.55pt 42.55pt 42.55pt;}div.da{}p.eg{margin-top:10.0pt;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-indent: 0cm}span.ee{font-size:10.0pt}p.eh{margin-top:0cm;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: center; text-indent: 0cm}p.ei{margin-top:0cm;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: center; text-indent: 0cm}p.ej{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}span.eb{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.ek{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.dz{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black} p.el{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.dw{font-size:11.0pt; font-family:"Calibri","sans-serif"}span.dx{color:black;background:white}span.em{font-family:"Calibri","sans-serif";color:black;font-size:11.0pt}p.en{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}table.eo{width:18.0cm;margin-left:-5.4pt;border-collapse:collapse}td.dr{width:272.55pt;padding:0cm 5.4pt 0cm 5.4pt}p.ep{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.eq{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}td.dp{width:216.15pt;padding:0cm 5.4pt 0cm 5.4pt} p.er{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: right}p.es{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.et{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.eu{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.ev{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.ew{margin-top:0cm;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: right; text-indent: 0cm}p.ex{margin-top:10.0pt;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin:0cm;margin-bottom:.0001pt; text-indent:0cm;line-height:normal}tr.dj{height:4.0pt}td.dl{width:272.55pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.0pt}td.dk{width:216.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.0pt} td.dh{width:251.45pt;padding:0cm 5.4pt 0cm 5.4pt}p.ey{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-19.25pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt}td.dg{width:237.25pt;padding:0cm 5.4pt 0cm 5.4pt}td.df{border:none}p.ez{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt}span.dd{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}span.fa{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.fb{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}p.fc{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify} /**/
RNS Number : 5633L
Genedrive PLC
09 September 2019
 

 

genedrive plc

("genedrive" or the "Company")

 

Notice of Results

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its preliminary results for the year ended 30 June 2019 on Thursday, 3 October 2019.

 

For further details please contact:

 

genedrive plc

www.genedriveplc.com

David Budd: CEO / Matthew Fowler: CFO

+44 (0)161 989 0245



Peel Hunt LLP

+44 (0)20 7418 8900

James Steel / Oliver Jackson




Stanford Capital Partners Limited

+44 (0)20 3815 8880

Patrick Claridge / John Howes




Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

Notes to Editors

 

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. The Company has assays on market for the detection of certain biological targets and has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORLFMATMBMMBBL

Quick facts: Genedrive PLC

Price: 21.5

Market: AIM
Market Cap: £7.5 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Genedrive reports 'high clinical accuracy' for its AIHL...

Headlines from Proactive UK newsroom. Genedrive (LON:GDR) has scored 100% diagnostic sensitivity and 100% specificity in a test of its assay kit to identify babies at risk of hearing loss from the use of antibiotic gentamicin. The clinical study was based on 303 samples. Gold miner...

1 week, 2 days ago